International Prospective Multicentre Study That Evaluate the Sentinel Lymph Node Detection Rate in Patients With First Local Recurrent Scamous Cell Carcinoma of the Vulva.
Key facts
- Who runs it
- Hospital Universitario La Paz
- Where
- Spain1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 100 people, planned
- Started
- 1 Aug 2025
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional
- Treatments tested
- Sentinel Lymph Node Biopsy in first local recurrent vulvar carcinoma
- Record updated
- 17 June 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- First local recurrent squamous cell carcinoma of the vulva (SCC)
- Unifocal, smaller or equal than 4 cm vulvar tumor not involving urethra, vagina or anus
- No distant or groin metastasis
- To be able to understand the study and sign informed consent
- Over 18 years old
- To be able to undergo planned follow up
Who cannot take part
- Previous bilateral IFL
- Multifocal recurrent disease of the vulva
- Synchronous, non-curable second malignancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Acronym: VULCA-NODE Study Title: Sentinel Node Biopsy in Relapsed Vulvar Cancer Primary Objetive: To evaluate the SLN detection rate in the first recurrent vulvar carcinoma setting.
Read full original descriptionShow less
Secondary Objetives:
* To compare the utility of different tracers in the detection of SLN for recurrent disease and the injection pattern. * To evaluate the surgical complications rate. * To analyze the nodal status by ultrastaging . * To assess the disease free and overall survival at 24 months from the first recurrence, as well as the dissemination pattern after the procedure.
Study Design: International prospective multicentre study
Inclusion Criteria:
* First local recurrent squamous cell carcinoma of the vulva (SCC). * Unifocal, smaller or equal than 4 cm vulvar tumor not involving urethra, vagina or anus. * No distant or groin metastasis. * To be able to understand the study and sign informed consent. * Over 18 years old. * To be able to undergo planned follow up.
Exclusion Criteria:
* Multifocal recurrent disease of the vulva. * Previous bilateral IFL. * Synchronous, non-curable second malignancy. Timing: 4 years
The group in the trial
- First local recurrent vulvar carcinomaTreatment being tested
Treatment: Sentinel Lymph Node Biopsy in first local recurrent vulvar carcinoma
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Sentinel Node Biopsy in Relapsed Vulvar Cancer. VULCA-NODE Study.
- Record updated
- 17 June 2025